882562-39-2

Basic information

• Product Name: 1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-ylboronic acid
• Synonyms: 1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-ylboronic acid;Boronic acid, B-[1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]-;[1-[(4-Methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]boronic acid;[1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-3-yl]boronic acid;(1-Tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)
• CAS NO: 882562-39-2
• Molecular Formula: C₁₄H₁₃BN₂O₄S
• Molecular Weight: 316.14
• Product Categories: CHIRAL CHEMICALS
• Mol File: 882562-39-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 596.1°C at 760 mmHg
• Flash Point: 314.3°C
• Appearance: /
• Density: 1.39±0.1 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 4.69E-15mmHg at 25°C
• Refractive Index: 1.647
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: 6.82±0.30(Predicted)
• CAS DataBase Reference: 1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-ylboronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-ylboronic acid(882562-39-2)
• EPA Substance Registry System: 1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-ylboronic acid(882562-39-2)

Safety Data

• Hazardous Substances Data: 882562-39-2(Hazardous Substances Data)

Usage

General Description

1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-ylboronic acid is a chemical compound with the molecular formula C16H14BNO4S. It is a boronic acid derivative that contains a pyrrolopyridine core and a tosyl group. 1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-ylboronic acid is often used as a building block in organic synthesis and medicinal chemistry, particularly in the development of pharmaceuticals and agrochemicals. It is known for its ability to form stable complexes with certain biomolecules, making it a valuable tool in the study of biological processes and drug discovery. Additionally, it has potential applications in materials science and chemical biology. Overall, 1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-ylboronic acid is a versatile and valuable compound with a wide range of uses in various scientific and industrial fields.

InChI:InChI=1/C14H13BN2O4S/c1-10-4-6-11(7-5-10)22(20,21)17-9-13(15(18)19)12-3-2-8-16-14(12)17/h2-9,18-19H,1H3

Upstream product

• 664982-01-8 3-iodo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 5419-55-6 Triisopropyl borate 
• 226085-18-3 3-bromo-1-(4-methylbenzenesulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 271-63-6 7-Azaindole 
• 74420-15-8 3-bromo-1H-pyrrolo[2,3-b]pyridine 
• 7732-18-5 water 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1227866-34-3 4-[(3,5-difluorobenzyl)amino]-6-{1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}pyridine-3-carboxyamide 
• 1227866-35-4 4-[(3,5-difluorobenzyl)amino]-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyridine-3-carboxyamide 
• 1417421-80-7 (R)-2-methyl-2-(2-(1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-ylamino)butanoic acid 
• 944842-54-0 decernotinib 
• 1417421-95-4 methyl 2-methyl-2-((2-(1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)butanoate 
• 1417421-89-6 C₂₁⁽¹³⁾C₄H₂₅F₃N₄⁽¹⁵⁾N₂O₃S 
• 866545-91-7 1-(4-methylbenzenesulfonyl)-3-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine 

Relevant articles and documents

DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES

The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.

METHODS FOR TREATING INFLAMMATORY DISEASES AND PHARMACEUTICAL COMBINATIONS USEFUL THEREFOR

The present invention provides a method of treating psoriasis comprising the administration of a compound of Formula I or a compound of Formula I and a co-therapy, and administrations of pharmaceutical compositions comprising a compound of Formula (I).

METHODS FOR TREATING INFLAMMATORY DISEASES AND PHARMACEUTICAL COMBINATIONS USEFUL THEREFOR

The present invention provides method of treating or lessening the severity of a disease selected from spondyloarthropathy, systemic lupus erythematosus, rheumatoid arthritis, or any combination thereof comprising the administration of a compound of Formu